bims-merabr Biomed News
on Metabolic rewiring in aggressive breast cancer
Issue of 2026–11–01
seven papers selected by
Barbara Mensah Sankofi, University of Oklahoma Health Sciences Center



  1. PLoS Genet. 2026 Oct;22(10): e1012351
      Invasive lobular carcinoma (ILC) is a common subtype of breast cancer, molecularly defined by genetic loss of CDH1, and subsequent loss of cell adhesion protein E-cadherin, in ~95% of ILC. Though CDH1 loss occurs early in ILC oncogenesis, it is unclear how this facilitates transformation. We modeled early CDH1 loss using "normal" human mammary epithelial cells (HMEC), i.e., finite lifespan cells reflecting early hyperplasia, and targeted E-cadherin signaling using antibodies versus causing genetic CDH1 loss using siRNA or CRISPR/Cas9-knockout. Transcriptome analysis across four HMEC models showed that the mode of E-cadherin targeting is critical for the subsequent phenotype. Antibody-mediated inhibition of cell-cell contacts induced gene signatures of epithelial-mesenchymal transition (EMT), consistent with the role of E-cadherin suppression during the EMT process. Conversely, genetic CDH1 loss - as in ILC oncogenesis - repressed EMT signatures, and instead remodeled gene expression toward a luminal epithelial phenotype. RNA-seq, single cell transcriptomics, flow cytometry, microscopy, and ATAC-seq analyses support that CDH1 loss induces lineage remodeling to a luminal state, which is mirrored in transcriptomic analysis of clinical ILC precursor lesions. By isolating luminal versus basal cells prior to CDH1 knockout, we found that CDH1 loss led to remodeling of lineage identity in both populations, converging on a new lineage homeostasis with a luminal progenitor-like phenotype. Consistent with the shift to a luminal progenitor phenotype, CDH1 loss enhanced proliferative capacity over the finite lifespan of the HMECs, highlighting a feature of early CDH1 loss that may contribute to clonal advantage during tumor initiation. Moreover, CDH1 loss enhanced anoikis resistance, a defining feature of ILC cells. Our findings support that genetic loss of CDH1 in mammary epithelial cells induces transcriptional and phenotypic changes consistent with lineage identity remodeling toward a luminal progenitor-like state, which may underpin the mechanism by which early CDH1 loss mediates ILC oncogenesis.
    DOI:  https://doi.org/10.1371/journal.pgen.1012351
  2. Breast Cancer Res. 2026 Aug 02. pii: 184. [Epub ahead of print]28(1):
       BACKGROUND: CK2 is a pleiotropic, heterotetrameric kinase elevated in numerous cancers and, as such, has garnered much attention as a target for novel antineoplastic agents. Currently, silmitasertib, a selective CK2 inhibitor, has an orphan designation for medulloblastoma and neuroblastoma. Tissue-specific overexpression of the catalytic subunit, CK2α, is sufficient to drive the development of mammary tumors in mice, underlying its potential role in breast oncogenesis. Our lab has demonstrated that CK2β protein expression is associated with endocrine resistance and that targeted disruption of CK2 activity results in ERα proteolysis. Among the factors driving endocrine resistance is overexpression of HER2/EGFR, which contributes to both proliferation and phenotypic plasticity in ER+ breast cancer. Here, we sought to determine the impact of CK2 targeting on HER2/EGFR signaling, phenotypic plasticity, and cell proliferation in endocrine-sensitive and endocrine-resistant breast cancer. Furthermore, we explored the potential of combined lapatinib and CK2-based therapies in decreasing breast cancer proliferation and epithelial-mesenchymal transition (EMT).
    METHODS: CK2 subunit expression and function were investigated in ERα-mutant, tamoxifen-resistant MCF-7 Y537S breast cancer cells and additional breast cancer subtypes. CK2 was inhibited pharmacologically using CX-4945 or genetically via shRNA knockdown of CK2β. Cell proliferation, spheroid growth, migration, and EMT markers were assessed using live-cell imaging, wound-healing assays, immunoblotting, and qRT-PCR. Publicly available patient datasets were analyzed to evaluate the prognostic relevance of CSNK2B expression.
    RESULTS: CK2β expression was significantly upregulated in ERα-mutant breast cancer cells and patient tumors. Pharmacological inhibition or genetic depletion of CK2β suppressed proliferation, spheroid formation, and migration, accompanied by reduced ERK phosphorylation and cyclin D1 expression. CK2β inhibition also attenuated EMT, marked by decreased N-cadherin, vimentin, and EMT transcription factors, while enhancing E-cadherin expression. High CSNK2B expression correlated with poorer relapse-free survival, particularly in ERα+ and HER2-E breast cancers. Notably, CK2β inhibition sensitized breast cancer cells to HER2-targeted therapy.
    CONCLUSIONS: CK2 is a critical regulator of endocrine-resistant breast cancer progression, promoting proliferation, EMT, and therapeutic resistance through ERK/cyclin D1 signaling. Inhibition of CK2 potentiated the effects of lapatinib across several cell lines. Furthermore, shRNA-mediated knockdown of the CK2β subunit phenocopies pharmacological disruption of CK2 and highlights the significance of the regulatory subunit in breast cancer cell biology. Targeting CK2, and, more selectively, CK2β represent a promising approach to overcome endocrine resistance and enhance responsiveness to HER2-directed treatments.
    Keywords:  Breast cancer; CK2; CX-4945; EMT; ERK signaling; ERα Y537S; Endocrine resistance
    DOI:  https://doi.org/10.1186/s13058-026-02356-y
  3. Cells. 2026 Oct 15. pii: 1882. [Epub ahead of print]15(20):
      Breast cancer incidence is rising globally. The emerging literature implicates cancer cell interactions with their surrounding microenvironment as a clinically significant driver of cell migration and metastasis. Current in vitro modelling approaches often rely on basic two-dimensional culture practices, a microenvironment far removed from the native tissue. This simplicity fails to recapitulate key aspects of the tumour environment that are critical to disease progression. This study has built upon three-dimensional culture technology to describe a breast cancer invasion assay with enhanced complexity compared with standard approaches. Three key breast epithelial cell lines, namely MCF-10A, MCF-7 and MDA-MB-231, representative of increasing invasiveness, were applied to in vitro systems of varying complexity. Through enhancing the geometry of the culture system, and inclusion of stromal populations, we have successfully improved breast cancer invasion modelling in vitro, exemplified by a demonstrated response to a test compound. The incorporation of a tissue-specific stromal foundation, upon which each epithelial cell lines were cultured, allowed for interaction between neosynthesised extracellular matrix and stromal and epithelial cells, whilst providing a dense physical network for cancer cells to migrate through. This has introduced several microenvironmental factors consistent with the native tissue but lacking in other more simplistic culture systems and has enhanced the value of commonplace cancer cell lines. This novel bioengineered culture system also lends itself to in-depth fundamental mechanistic insights into aspects of cancer cell biology, including interactions with the tissue environment and the role of cancer-associated fibroblasts in disease progression.
    Keywords:  breast cancer; cancer-associated fibroblasts; extracellular matrix; in vitro; invasion; migration; tissue bioengineering
    DOI:  https://doi.org/10.3390/cells15201882
  4. Front Immunol. 2026 ;17 1843935
       Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease that often exhibits a relatively immunologically "cold" tumor microenvironment, which can limit the efficacy of immune checkpoint inhibitors (ICIs). Alterations in lipid metabolism and lipid peroxidation may influence tumor-immune interactions and represent potential determinants of response to immune checkpoint blockade.
    Methods: Human TNBC cell lines (MDA-MB-231, BT-549) were treated with ferroptosis inducers (FINs), including RSL3 and SCD1 inhibitor (SCD1i), and cell death was assessed. Proteomic profiling of cell lysates and conditioned media was performed, and IL-8 and MIF secretion was quantified by ELISA. Splenocytes were incubated with conditioned media to assess immune activation via flow cytometry. In vivo efficacy of SCD1i, PD-1 blockade, and their combination was evaluated using the E0771 murine TNBC model.
    Results: SCD1i and RSL3 treatment induced the release of inflammatory mediators, including IL-8 and MIF, as confirmed by ELISA. Conditioned media from treated TNBC cells enhanced immune activation in splenocytes, characterized by increased effector CD4+ and CD8+ T-cell populations and altered expression of immune checkpoint receptors. In vivo, SCD1 inhibition increased CD8+ T cell infiltration into the tumor microenvironment and increased PD-1 and LAG-3 expression in both CD4+ and CD8+ T cells. Notably, combined SCD1 inhibition and anti-PD-1 therapy resulted in greater tumor growth inhibition compared with either treatment alone.
    Conclusion: SCD1 inhibition promotes lipid peroxidation and release of inflammatory factors that enhance immune activation and sensitize TNBC to checkpoint blockade. Targeting the SCD1 represents a promising strategy to improve ICI efficacy in TNBC.
    Keywords:  MIF; SCD1; TNBC; anti-PD1; ferroptosis; ferroptosis inducers; immunotherapy
    DOI:  https://doi.org/10.3389/fimmu.2026.1843935
  5. J Leukoc Biol. 2026 Oct 05. pii: qiag117. [Epub ahead of print]118(10):
      Immune escape in breast cancer is a primary contributor to immunotherapy resistance and poor patient prognosis. Fucosylation is essential for tumor progression, but the regulatory mechanism of its key enzyme, guanosine diphosphate-L-fucose synthase (TSTA3), within the breast cancer immune microenvironment remains unexplored. This study combined bioinformatics and experimental approaches to investigate TSTA3 in breast cancer. TSTA3 expression was validated by quantitative real-time reverse transcription polymerase chain reaction and western blotting. Functional assays in a tumor-T-cell coculture system showed that TSTA3 knockdown enhanced CD8+ T-cell cytotoxicity and suppressed tumor malignancy. Mechanistically, TSTA3 fucosylated programmed death ligand-1, and this modification was confirmed by Ulex europaeus agglutinin-1 chromatography and co-immunoprecipitation. SOX2 was identified as an upstream transcription factor of TSTA3 via chromatin immunoprecipitation and dual-luciferase assays. The SOX2/TSTA3/programmed death ligand-1 axis was functionally validated in rescue experiments and in vivo tumor models. TSTA3 was highly expressed in breast cancer tumors. Its knockdown enhanced CD8+ T-cell cytotoxicity and suppressed tumor proliferation, migration, and invasion in vitro. Mechanistically, TSTA3 upregulated programmed death ligand-1 expression in a fucose-dependent manner and, partly through programmed death ligand-1, suppressed CD8+ T-cell-mediated antitumor immune responses. SOX2 directly activated TSTA3 transcription, leading to programmed death ligand-1 stabilization via fucosylation. In vivo, targeting the SOX2/TSTA3/programmed death ligand-1 axis inhibited tumor growth and boosted CD8+ T-cell activity. Collectively, this study uncovered a novel mechanism whereby SOX2 transcriptionally activated TSTA3, which fucosylated programmed death ligand-1 and, partly through programmed death ligand-1, suppressed CD8+ T-cell-mediated antitumor immune responses, providing a theoretical basis for targeting the SOX2/TSTA3/programmed death ligand-1 axis to enhance immunotherapy in breast cancer.
    Keywords:  CD8+ T cells; PD-L1; TSTA3; breast cancer; fucosylation
    DOI:  https://doi.org/10.1093/jleuko/qiag117
  6. Breast Cancer Res Treat. 2026 Oct 26. pii: 17. [Epub ahead of print]220(1):
       BACKGROUND: Endocrine therapy for hormone receptor-positive breast cancer is associated with adverse metabolic effects - including increased fat mass, decreased lean muscle mass, and insulin resistance - that may attenuate the efficacy of GLP-1 receptor agonists (GLP-1 RAs). This study evaluated GLP-1 RA-associated weight loss outcomes in breast cancer patients receiving concurrent endocrine therapy.
    METHODS: We conducted a retrospective cohort analysis of 269 breast cancer patients at a single academic center receiving concurrent GLP-1 RA and adjuvant endocrine therapy. GLP-1 RA and endocrine therapy data were obtained from electronic medication reconciliation lists and pharmacy dispense reports. Patients were required to have initiated GLP-1 therapy during the study period and to have received concurrent GLP-1 RA and endocrine therapy for at least one year. The primary outcome was percentage weight change from GLP-1 initiation to 12 months (± 2 months). Secondary outcomes included proportions achieving ≥ 5%, ≥ 10%, and ≥ 15% weight loss.
    RESULTS: Mean one-year percentage weight loss was - 4.5% (95% CI: -6.0% to - 3.0%; -3.9 kg; 95% CI: -4.96 to - 2.93 kg), significantly below the 10-20% observed in postmenopausal subgroups of GLP-1 randomized trials (all p < 0.001). Only 21.3% achieved ≥ 10% and 10.4% achieved ≥ 15% weight loss. Weight loss differed significantly by GLP-1 agent (p = 0.003); semaglutide (- 5.8%) and tirzepatide (- 4.7%) outperformed dulaglutide (+ 0.1%), which is approved for type 2 diabetes only. Higher baseline weight was associated with greater absolute loss (r = - 0.19, p = 0.002), though percentage weight loss did not differ significantly by baseline BMI category (p = 0.303). PR-negative patients lost more than PR-positive patients (- 8.2% vs. -4.2%; p = 0.021, d = 0.46). Type 2 diabetes was present in 70.6% of patients; T2DM status was not significantly associated with weight loss on t-test (p = 0.288), though patients without T2DM were numerically more likely to achieve ≥ 15% loss (21.5% vs. 5.8%).
    CONCLUSIONS: GLP-1 RAs produce statistically significant but substantially attenuated weight loss in breast cancer patients on concurrent endocrine therapy. GLP-1 agent selection significantly influences outcomes. Given emerging evidence of oncologic benefit, prospective trials are needed.
    Keywords:  Aromatase inhibitors; Breast cancer; Endocrine therapy; GLP-1 receptor agonists; Metabolic effects; Obesity; Ovarian suppression; Tamoxifen; Type 2 diabetes; Weight loss
    DOI:  https://doi.org/10.1007/s10549-026-08096-z
  7. Anticancer Res. 2026 Nov;46(11): 6041-6050
       BACKGROUND/AIM: Cancer stem cells (CSCs) are heterogeneous and exhibit distinct phenotypic and functional characteristics. The side population (SP) and CD44+/CD24- phenotypes are widely used to enrich breast cancer cells with CSC-associated properties; however, whether these approaches identify functionally equivalent populations remains unclear. Building on our previous establishment of a DyeCycle Violet (DCV)-based method for isolating SP cells from MCF-7 breast cancer cells, this study compared the biological characteristics of DCV-defined SP cells and a CD44+/CD24--enriched fraction.
    MATERIALS AND METHODS: SP cells were isolated from MCF-7 cells by fluorescence-activated cell sorting using DCV and fumitremorgin C. A CD44+/CD24--enriched fraction was isolated by magnetic-activated cell sorting. Parental MCF-7 cells, SP cells, and the CD44+/CD24--enriched fraction were compared for proliferation and invasion. Tumor-forming ability was evaluated in nude mice following subcutaneous inoculation of 100 or 500 cells. Xenograft tumors were examined histopathologically and immunohistochemically.
    RESULTS: No significant differences in proliferative activity were observed among parental MCF-7, SP, and the CD44+/CD24--enriched fraction at either 48 or 72 h. Invasion was highest in the CD44+/CD24--enriched fraction (87.63±20.29%), followed by SP cells (51.86±6.83%) and parental MCF-7 cells (32.52±9.95%; p=0.001). Tumors developed in all three mice receiving the CD44+/CD24--enriched fraction at both cell doses, whereas tumor formation was less frequent in the other groups. Xenograft tumors showed morphological and immunohistochemical characteristics consistent with MCF-7 cells.
    CONCLUSION: DCV-defined SP cells and the CD44+/CD24--enriched fraction exhibited distinct biological characteristics. The CD44+/CD24--enriched fraction showed high invasive activity and frequent tumor formation, whereas SP cells showed relatively high proliferative activity and retained tumor-forming capacity under the experimental conditions examined. These findings suggest that SP and CD44+/CD24- enrichment methods select populations with different functional properties.
    Keywords:  Breast cancer; CD24; CD44; MCF-7; cancer stem cells; invasion; side population; tumorigenicity
    DOI:  https://doi.org/10.21873/anticanres.18436